https://www.selleckchem.com/pr....oducts/mcc950-sodium
7 months [95% CI 1.4-2.0 months] vs. 6.3 months [95% CI 5.2-7.3 months], P less then 0.001; hazard ratio 0.14, 95% CI 0.08-0.25) and significantly shorter median overall survival (8.2 months [95% CI 3.0-13.4 months] vs. 22.6 months [95% CI 17.0-28.1 months], P less then 0.001; hazard ratio 0.27, 95% CI 0.15-0.49). Multivariate analysis revealed that RP was independently predicted by the presence of ≥3 metastatic sites (P = 0.039) and a neutrophil-to-lymphocyte ratio of ≥3 (P = 0.044). CONCLUSIONS Among NSCLC patients, RP
Like
Comment
Share
